PFE Stock Recent News
PFE LATEST HEADLINES
Pfizer's high dividend yield and robust pipeline could offer significant returns for patient investors.
As we move further into October, many investors may be looking to identify certain stocks with the potential to provide additional capital appreciation upside, but also some strong dividend income.
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund Starboard Value.
This investor's campaign is stoking some undesirable corporate intrigue.
CNBC Angelica Peebles joins 'Power Lunch' to report on Pfizer's activist battle.
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer stock skidded Thursday after former executives Ian Read and Frank D'Amelio sided with the drugmaker over activist investor Starboard.
Pfizer Inc.'s stock dipped early Thursday, after two of its former executives said they would not support an effort by activist shareholder Starboard Value to orchestrate a turnaround.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in patients with metastatic castration-resistant prostate cancer (mCRPC). Results showed a statistically significant and clinically meaningful improvemen.
Two former Pfizer executives who were previously linked to activist investor Starboard Value's campaign at the struggling drugmaker said they would step back from the push late Wednesday evening. Former CEO Ian Read and ex-CFO Frank D'Amelio voiced their full support for current CEO Albert Bourla and the management team.